ATE273027T1 - Zusammensetzung zur behandlung von entzündungen - Google Patents

Zusammensetzung zur behandlung von entzündungen

Info

Publication number
ATE273027T1
ATE273027T1 AT99957793T AT99957793T ATE273027T1 AT E273027 T1 ATE273027 T1 AT E273027T1 AT 99957793 T AT99957793 T AT 99957793T AT 99957793 T AT99957793 T AT 99957793T AT E273027 T1 ATE273027 T1 AT E273027T1
Authority
AT
Austria
Prior art keywords
inflammation
composition
treating inflammation
treating
bcc
Prior art date
Application number
AT99957793T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Fillion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE273027T1 publication Critical patent/ATE273027T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT99957793T 1998-12-04 1999-12-03 Zusammensetzung zur behandlung von entzündungen ATE273027T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11094398P 1998-12-04 1998-12-04
PCT/CA1999/001156 WO2000033879A1 (en) 1998-12-04 1999-12-03 Method for the treatment of inflammation

Publications (1)

Publication Number Publication Date
ATE273027T1 true ATE273027T1 (de) 2004-08-15

Family

ID=22335783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957793T ATE273027T1 (de) 1998-12-04 1999-12-03 Zusammensetzung zur behandlung von entzündungen

Country Status (11)

Country Link
US (1) US6890911B1 (de)
EP (1) EP1135164B1 (de)
JP (2) JP4488626B2 (de)
AT (1) ATE273027T1 (de)
AU (1) AU768327B2 (de)
CA (1) CA2354047C (de)
DE (1) DE69919386T2 (de)
DK (1) DK1135164T3 (de)
ES (1) ES2226464T3 (de)
PT (1) PT1135164E (de)
WO (1) WO2000033879A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105943559A (zh) 2010-10-13 2016-09-21 特莱斯塔治疗知识产权公司 细菌核糖核酸细胞壁组合物及其制备和使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
JPH0517363A (ja) * 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
BR9406496A (pt) * 1993-01-29 1996-01-02 Vetrepharm Inc Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
AU727781B2 (en) * 1997-04-02 2000-12-21 Bioniche Life Sciences Inc. Use of bacterial cell wall extract for preventing, treating, or eliminating a protozoal or parasitic disease
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
WO2000059518A2 (en) * 1999-04-01 2000-10-12 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells

Also Published As

Publication number Publication date
AU768327B2 (en) 2003-12-11
US6890911B1 (en) 2005-05-10
JP4488626B2 (ja) 2010-06-23
WO2000033879A1 (en) 2000-06-15
JP2010001314A (ja) 2010-01-07
CA2354047C (en) 2007-08-14
EP1135164A1 (de) 2001-09-26
DE69919386D1 (de) 2004-09-16
JP2002531528A (ja) 2002-09-24
DE69919386T2 (de) 2005-02-17
AU1541100A (en) 2000-06-26
CA2354047A1 (en) 2000-06-15
EP1135164B1 (de) 2004-08-11
JP5050148B2 (ja) 2012-10-17
DK1135164T3 (da) 2004-12-20
PT1135164E (pt) 2004-11-30
ES2226464T3 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
IL180924A0 (en) Method for regulating cell proliferation and cell death
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
YU48701A (sh) Fenilfenantridini sa dejstvom inhibicije pde-iv
ES2150157T3 (es) Piridinas 2-aril sustituidas.
ATE233735T1 (de) Neue phenanthridine
TR199700585A2 (xx) Sikloalkano-piridinler.
ES2139904T3 (es) Sistema de suministro celular de ciclodextrina para oligonucleotidos.
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
ATE315558T1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
TR200101547T2 (tr) Askomisinleri içeren topik kompozisyonlar
PT778844E (pt) Complexos funcionais de metais de terpiridina processos para a sua preparacao e conjugados oligonucleotideos com complexos de metais de terpiridina
GB2324091B (en) Metalloproteinase inhibitors
ATE273027T1 (de) Zusammensetzung zur behandlung von entzündungen
DE69829316D1 (de) Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand
MY118864A (en) Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
CY1107455T1 (el) Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη
KR970702880A (ko) 신규한 펩티드 활성 물질 및 그의 제조 방법(New Peptide Active Substance And Production Thereof)
DE69906532D1 (de) Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
TR200002675T2 (tr) Paroksetinin kristalin formu.
TR199900905T2 (xx) HTLV-1 enfeksiyonlar�n�n tedavisi i�in bir ilac�n yap�m�nda PKC inhibit�rlerinin kullan�m�.
MD775F1 (en) The 2-hydroxynaphthyl-1-methinehydrazone of 5-nitro- 2-furaldehyde synthesis method
RU2002133953A (ru) Способ лечения больных генерализованным пародонтитом

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1135164

Country of ref document: EP